Details of the Drug Combination

General Information of Drug Combination (ID: DCSQ37Q)

• Drug Combination Name: Repaglinide + Rosiglitazone
• Indication: Diabetes Mellitus, Type 2; Status: Phase 1 [1]
• Component Drugs:
  Repaglinide (DM5SXUV): Small molecular drug
  Rosiglitazone (DMILWZR): N.A.

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Repaglinide

Disease Entry	ICD 11	Status	REF
Diabetic complication	5A2Y	Approved	[2]

Repaglinide Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ATP-binding cassette transporter C9 (ABCC9)	TTEF5MJ	ABCC9_HUMAN	Blocker	[3]
ATP-binding cassette transporter C8 (ABCC8)	TTP835K	ABCC8_HUMAN	Blocker	[3]

Repaglinide Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[4]

Repaglinide Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[6]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[5]

Repaglinide Interacts with 6 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Solute carrier organic anion transporter family member 1B1 (SLCO1B1)	OTNEN8QK	SO1B1_HUMAN	Affects Metabolism	[7]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[8]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[9]
HLA class I histocompatibility antigen, alpha chain F (HLA-F)	OT76CM19	HLAF_HUMAN	Affects Expression	[10]
Solute carrier family 15 member 1 (SLC15A1)	OT1P16B5	S15A1_HUMAN	Decreases Activity	[11]
Major histocompatibility complex class I-related gene protein (MR1)	OTZU3XX7	HMR1_HUMAN	Affects Expression	[10]

Indication(s) of Rosiglitazone

Disease Entry	ICD 11	Status	REF
Chronic kidney disease	GB61	Terminated	[]

Rosiglitazone Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[19]

Rosiglitazone Interacts with 4 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[20]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[21]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[21]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Metabolism	[22]

Rosiglitazone Interacts with 589 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Increases Expression	[23]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[24]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Decreases Activity	[24]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Increases Expression	[24]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Decreases Activity	[25]
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2)	OT02MSKN	3BHS2_HUMAN	Decreases Activity	[25]
Retinoic acid receptor beta (RARB)	OT367U3E	RARB_HUMAN	Increases Expression	[26]
Liver carboxylesterase 1 (CES1)	OT9L0LR8	EST1_HUMAN	Increases Expression	[27]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Decreases Expression	[27]
Perilipin-2 (PLIN2)	OTRXJ9UN	PLIN2_HUMAN	Increases Expression	[27]
Choriogonadotropin subunit beta 3 (CGB3)	OTVM2SU3	CGB3_HUMAN	Increases Expression	[28]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[29]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Increases Expression	[29]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[29]
Golgin subfamily A member 8A (GOLGA8A)	OTSNE9EQ	GOG8A_HUMAN	Decreases Expression	[12]
CMRF35-like molecule 7 (CD300LB)	OTVC407Y	CLM7_HUMAN	Increases Expression	[12]
Signal-regulatory protein beta-1 (SIRPB1)	OTGHALWJ	SIRB1_HUMAN	Increases Expression	[12]
Regulatory factor X-associated protein (RFXAP)	OTX46DKQ	RFXAP_HUMAN	Decreases Expression	[12]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Decreases Expression	[12]
Phospholipid phosphatase 3 (PLPP3)	OTSSF7BK	PLPP3_HUMAN	Increases Expression	[12]
Low-density lipoprotein receptor class A domain-containing protein 4 (LDLRAD4)	OTQUX50Z	LRAD4_HUMAN	Increases Expression	[12]
Tumor necrosis factor ligand superfamily member 12 (TNFSF12)	OT6FQ02V	TNF12_HUMAN	Decreases Expression	[12]
F-box-like/WD repeat-containing protein TBL1X (TBL1X)	OTXQ51E0	TBL1X_HUMAN	Decreases Expression	[12]
Leukocyte immunoglobulin-like receptor subfamily A member 1 (LILRA1)	OTZ4NA7Q	LIRA1_HUMAN	Increases Expression	[12]
Short-chain dehydrogenase/reductase 3 (DHRS3)	OTSK1DTP	DHRS3_HUMAN	Increases Expression	[12]
Retinal dehydrogenase 2 (ALDH1A2)	OTJB560Z	AL1A2_HUMAN	Increases Expression	[12]
Rho-related BTB domain-containing protein 3 (RHOBTB3)	OT1BFKPH	RHBT3_HUMAN	Increases Expression	[12]
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthase 2 (PAPSS2)	OTDLEXPN	PAPS2_HUMAN	Increases Expression	[12]
Mitogen-activated protein kinase kinase kinase 6 (MAP3K6)	OTOE0Z1R	M3K6_HUMAN	Decreases Expression	[12]
BAG family molecular chaperone regulator 2 (BAG2)	OTI6LD27	BAG2_HUMAN	Increases Expression	[12]
Adenosine deaminase (ADA)	OTOX2872	ADA_HUMAN	Increases Expression	[12]
T-cell surface glycoprotein CD1a (CD1A)	OTKSSG6N	CD1A_HUMAN	Decreases Expression	[12]
Beta-glucuronidase (GUSB)	OT9N1DK3	BGLR_HUMAN	Increases Expression	[12]
Retinol-binding protein 1 (RBP1)	OTRP1MFC	RET1_HUMAN	Increases Expression	[12]
Tumor-associated calcium signal transducer 2 (TACSTD2)	OTLSZR00	TACD2_HUMAN	Decreases Expression	[12]
Peroxisomal coenzyme A diphosphatase NUDT7 (NUDT7)	OTCPOQ6W	NUDT7_HUMAN	Decreases Expression	[12]
Interleukin-1 receptor type 1 (IL1R1)	OTTU8959	IL1R1_HUMAN	Decreases Expression	[12]
Protein C-ets-2 (ETS2)	OTPVHOZ7	ETS2_HUMAN	Increases Expression	[12]
Antigen-presenting glycoprotein CD1d (CD1D)	OT3ROU4J	CD1D_HUMAN	Increases Expression	[12]
Plasma membrane calcium-transporting ATPase 1 (ATP2B1)	OT5MXG9W	AT2B1_HUMAN	Decreases Expression	[12]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2)	OT6MFOWF	TGM2_HUMAN	Increases Expression	[12]
Collagen alpha-3(V) chain (COL5A3)	OTCGC4DM	CO5A3_HUMAN	Increases Expression	[12]
Integrin alpha-E (ITGAE)	OT41KCRX	ITAE_HUMAN	Increases Expression	[12]
Rap1 GTPase-activating protein 1 (RAP1GAP)	OTC31ONQ	RPGP1_HUMAN	Decreases Expression	[12]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Increases Expression	[12]
Ribose-5-phosphate isomerase (RPIA)	OT805SMH	RPIA_HUMAN	Increases Expression	[12]
Thrombospondin-3 (THBS3)	OTDKMUBD	TSP3_HUMAN	Increases Expression	[12]
PDZ and LIM domain protein 4 (PDLIM4)	OT23LZYY	PDLI4_HUMAN	Decreases Expression	[12]
Histone H2B type 1-D (H2BC5)	OTXDTDHN	H2B1D_HUMAN	Decreases Expression	[12]
Ras-related protein Rab-15 (RAB15)	OTU0GGR3	RAB15_HUMAN	Decreases Expression	[12]
Oxidized low-density lipoprotein receptor 1 (OLR1)	OTS44RIC	OLR1_HUMAN	Increases Expression	[12]
Amyloid beta precursor like protein 2 (APLP2)	OTTFE53M	APLP2_HUMAN	Increases Expression	[12]
Myotonin-protein kinase (DMPK)	OT9XJKG4	DMPK_HUMAN	Decreases Expression	[12]
Dystrophia myotonica WD repeat-containing protein (DMWD)	OT0CBZ6F	DMWD_HUMAN	Decreases Expression	[12]
Alpha-(1,3)-fucosyltransferase 7 (FUT7)	OTJF6BSN	FUT7_HUMAN	Decreases Expression	[12]
P-selectin glycoprotein ligand 1 (SELPLG)	OTOK3301	SELPL_HUMAN	Decreases Expression	[12]
H2.0-like homeobox protein (HLX)	OT7DTH46	HLX_HUMAN	Decreases Expression	[12]
Uncharacterized protein KIAA0040 (KIAA0040)	OT27EBY3	K0040_HUMAN	Decreases Expression	[12]
Serum paraoxonase/arylesterase 2 (PON2)	OT55NCTD	PON2_HUMAN	Decreases Expression	[12]
Nicotinate-nucleotide pyrophosphorylase (QPRT)	OT6SKKLL	NADC_HUMAN	Decreases Expression	[12]
Calcitonin gene-related peptide type 1 receptor (CALCRL)	OTMGGM47	CALRL_HUMAN	Decreases Expression	[12]
Zinc finger protein SNAI3 (SNAI3)	OTG9DI66	SNAI3_HUMAN	Increases Expression	[12]
Pleckstrin homology-like domain family A member 2 (PHLDA2)	OTMV9DPP	PHLA2_HUMAN	Decreases Expression	[12]
Late cornified envelope-like proline-rich protein 1 (LELP1)	OTOQIVV0	LELP1_HUMAN	Decreases Expression	[12]
Protein sel-1 homolog 3 (SEL1L3)	OT10N6Z2	SE1L3_HUMAN	Increases Expression	[12]
Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1)	OTXIGC6I	LAIR1_HUMAN	Increases Expression	[12]
Myogenesis-regulating glycosidase (MYORG)	OTVK4VMH	MYORG_HUMAN	Decreases Expression	[12]
Uncharacterized protein C16orf46 (C16ORF46)	OT8FDG3A	CP046_HUMAN	Decreases Expression	[12]
Phospholipase B-like 1 (PLBD1)	OTHYEB4W	PLBL1_HUMAN	Increases Expression	[12]
Low-density lipoprotein receptor-related protein 11 (LRP11)	OTQNI7L8	LRP11_HUMAN	Decreases Expression	[12]
Sodium-independent sulfate anion transporter (SLC26A11)	OTWBV9CR	S2611_HUMAN	Increases Expression	[12]
Cerebellar degeneration-related protein 2-like (CDR2L)	OT5UVB1J	CDR2L_HUMAN	Decreases Expression	[12]
SLIT and NTRK-like protein 4 (SLITRK4)	OTSCN5AM	SLIK4_HUMAN	Increases Expression	[12]
Retinol dehydrogenase 10 (RDH10)	OTL9FSGF	RDH10_HUMAN	Increases Expression	[12]
Glycerol-3-phosphate dehydrogenase 1-like protein (GPD1L)	OTVLWW9T	GPD1L_HUMAN	Decreases Expression	[12]
Sesquipedalian-1 (PHETA1)	OT4IMC0X	SESQ1_HUMAN	Decreases Expression	[12]
Refilin-B (RFLNB)	OTI7ZM75	RFLB_HUMAN	Increases Expression	[12]
Uncharacterized protein FAM241A (FAM241A)	OTC12ETA	F241A_HUMAN	Decreases Expression	[12]
F-box only protein 15 (FBXO15)	OTJHEFE5	FBX15_HUMAN	Increases Expression	[12]
RalBP1-associated Eps domain-containing protein 2 (REPS2)	OTSE3TRP	REPS2_HUMAN	Decreases Expression	[12]
CMRF35-like molecule 1 (CD300LF)	OTQWJGSR	CLM1_HUMAN	Increases Expression	[12]
Serine-rich single-pass membrane protein 1 (SSMEM1)	OTH78CH0	SSMM1_HUMAN	Decreases Expression	[12]
Interactor protein for cytohesin exchange factors 1 (IPCEF1)	OTOUIHID	ICEF1_HUMAN	Decreases Expression	[12]
Cortactin-binding protein 2 (CTTNBP2)	OT4CL1EW	CTTB2_HUMAN	Decreases Expression	[12]
Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1)	OT6FQ1K3	M4K1_HUMAN	Decreases Expression	[12]
Kinesin-like protein KIFC2 (KIFC2)	OTLTVM7V	KIFC2_HUMAN	Decreases Expression	[12]
Metalloendopeptidase OMA1, mitochondrial (OMA1)	OT0JRVY7	OMA1_HUMAN	Increases Expression	[12]
PDZ and LIM domain protein 2 (PDLIM2)	OTEURRPD	PDLI2_HUMAN	Decreases Expression	[12]
Fatty acyl-CoA reductase 2 (FAR2)	OTRYY709	FACR2_HUMAN	Increases Expression	[12]
PML-RARA-regulated adapter molecule 1 (PRAM1)	OTZN3DWD	PRAM_HUMAN	Increases Expression	[12]
Growth/differentiation factor 15 (GDF15)	OTWQN50N	GDF15_HUMAN	Increases Expression	[12]
Dehydrogenase/reductase SDR family member 9 (DHRS9)	OTB1WOZA	DHRS9_HUMAN	Increases Expression	[12]
Caspase recruitment domain-containing protein 14 (CARD14)	OTADQHOV	CAR14_HUMAN	Increases Expression	[12]
TBC1 domain family member 2A (TBC1D2)	OTSGHPD0	TBD2A_HUMAN	Increases Expression	[12]
N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 (B3GNT4)	OTRKV2N8	B3GN4_HUMAN	Increases Expression	[12]
Gamma-aminobutyric acid receptor-associated protein-like 1 (GABARAPL1)	OT4U7SBG	GBRL1_HUMAN	Increases Expression	[12]
Dendritic cell-specific transmembrane protein (DCSTAMP)	OTFKRP2H	DCSTP_HUMAN	Increases Expression	[12]
Homeodomain-interacting protein kinase 2 (HIPK2)	OTDB7QC3	HIPK2_HUMAN	Increases Expression	[12]
Ribokinase (RBKS)	OTDG01Y9	RBSK_HUMAN	Increases Expression	[12]
Tensin-1 (TNS1)	OTZ8S1PL	TENS1_HUMAN	Decreases Expression	[12]
Echinoderm microtubule-associated protein-like 4 (EML4)	OTJC45TA	EMAL4_HUMAN	Increases Expression	[12]
Interleukin-1 receptor accessory protein (IL1RAP)	OTEU321R	IL1AP_HUMAN	Decreases Expression	[12]
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IC (MAN1C1)	OT44TM7D	MA1C1_HUMAN	Decreases Expression	[12]
1-acyl-sn-glycerol-3-phosphate acyltransferase delta (AGPAT4)	OT5CTQKO	PLCD_HUMAN	Increases Expression	[12]
Ras-related protein Rab-20 (RAB20)	OTP9OOVS	RAB20_HUMAN	Increases Expression	[12]
ETS homologous factor (EHF)	OTY6TPWD	EHF_HUMAN	Increases Expression	[12]
Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (MGAT4C)	OTQ2R629	MGT4C_HUMAN	Decreases Expression	[12]
DnaJ homolog subfamily C member 5B (DNAJC5B)	OTHDMM7O	DNJ5B_HUMAN	Increases Expression	[12]
CMRF35-like molecule 8 (CD300A)	OTGBQE0Z	CLM8_HUMAN	Increases Expression	[12]
Meteorin (METRN)	OTI2645G	METRN_HUMAN	Decreases Expression	[12]
Adherens junction-associated protein 1 (AJAP1)	OTAAW121	AJAP1_HUMAN	Increases Expression	[12]
Paladin (PALD1)	OTLGUM8H	PALD_HUMAN	Decreases Expression	[12]
Protein NDRG2 (NDRG2)	OT5L6KD7	NDRG2_HUMAN	Decreases Expression	[12]
Phosphatidylinositide phosphatase SAC2 (INPP5F)	OTPKUY50	SAC2_HUMAN	Increases Expression	[12]
Transducin beta-like protein 2 (TBL2)	OTCIMSK8	TBL2_HUMAN	Increases Expression	[12]
Transmembrane protein 14A (TMEM14A)	OTANQA6G	TM14A_HUMAN	Decreases Expression	[12]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Increases Expression	[30]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Decreases Expression	[30]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)	OTA675TJ	GTR1_HUMAN	Decreases Expression	[30]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1)	OTO7FJA9	DHI1_HUMAN	Decreases Expression	[30]
Lipid transferase CIDEC (CIDEC)	OTMDZ56K	CIDEC_HUMAN	Increases Expression	[30]
Resistin (RETN)	OTW5Z1NH	RETN_HUMAN	Decreases Expression	[30]
Proline dehydrogenase 1, mitochondrial (PRODH)	OT7SQ1C7	PROD_HUMAN	Increases Expression	[31]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases Expression	[32]
Matrix metalloproteinase-9 (MMP9)	OTB2QDAV	MMP9_HUMAN	Decreases Expression	[33]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Decreases Expression	[33]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[34]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Decreases Activity	[35]
Amine oxidase B (MAOB)	OTTDFM1O	AOFB_HUMAN	Decreases Activity	[35]
Cytochrome P450 2J2 (CYP2J2)	OTJBTEH8	CP2J2_HUMAN	Increases Expression	[36]
Cytochrome c oxidase subunit 1 (COX1)	OTG3O9BN	COX1_HUMAN	Increases Expression	[37]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Increases Expression	[37]
Succinate dehydrogenase flavoprotein subunit, mitochondrial (SDHA)	OTOJ8QFF	SDHA_HUMAN	Increases Expression	[37]
Transcription factor A, mitochondrial (TFAM)	OTXXV5V7	TFAM_HUMAN	Increases Expression	[37]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Increases Expression	[37]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[38]
Fucose mutarotase (FUOM)	OTM201HH	FUCM_HUMAN	Decreases Expression	[13]
Myotubularin-related protein 11 (MTMR11)	OTHL2O08	MTMRB_HUMAN	Decreases Expression	[13]
Aspartate dehydrogenase domain-containing protein (ASPDH)	OTN38YBY	ASPDH_HUMAN	Decreases Expression	[13]
D-dopachrome decarboxylase-like protein (DDTL)	OTG1LU87	DDTL_HUMAN	Decreases Expression	[13]
Espin (ESPN)	OT7Z6LX2	ESPN_HUMAN	Decreases Expression	[13]
Mannan-binding lectin serine protease 2 (MASP2)	OTBFTUZ1	MASP2_HUMAN	Decreases Expression	[13]
Sodium/nucleoside cotransporter 1 (SLC28A1)	OTXWVV9O	S28A1_HUMAN	Decreases Expression	[13]
Matrilin-2 (MATN2)	OTVDR68G	MATN2_HUMAN	Decreases Expression	[13]
Phospholipid phosphatase 1 (PLPP1)	OT0IIMI5	PLPP1_HUMAN	Increases Expression	[13]
Kynurenine 3-monooxygenase (KMO)	OT3MRMM9	KMO_HUMAN	Decreases Expression	[13]
Solute carrier family 22 member 1 (SLC22A1)	OT7817I4	S22A1_HUMAN	Decreases Expression	[13]
Calpain-5 (CAPN5)	OTQ8QM7K	CAN5_HUMAN	Decreases Expression	[13]
Insulin-induced gene 1 protein (INSIG1)	OTZF5X1D	INSI1_HUMAN	Decreases Expression	[13]
Protein MTSS 1 (MTSS1)	OT5DTDO2	MTSS1_HUMAN	Decreases Expression	[13]
Synaptotagmin-7 (SYT7)	OTBWAOWY	SYT7_HUMAN	Decreases Expression	[13]
Glucose-6-phosphate exchanger SLC37A4 (SLC37A4)	OTLCYA32	G6PT1_HUMAN	Decreases Expression	[13]
Perilipin-1 (PLIN1)	OT3OAAZ4	PLIN1_HUMAN	Increases Expression	[13]
Peroxisomal membrane protein 11A (PEX11A)	OT8MJ9CJ	PX11A_HUMAN	Increases Expression	[13]
Tumor necrosis factor receptor superfamily member 21 (TNFRSF21)	OT3EDGXO	TNR21_HUMAN	Increases Expression	[13]
Lathosterol oxidase (SC5D)	OT41KMW4	SC5D_HUMAN	Decreases Expression	[13]
Organic cation/carnitine transporter 2 (SLC22A5)	OTC36TYB	S22A5_HUMAN	Increases Expression	[13]
ABC-type organic anion transporter ABCA8 (ABCA8)	OTCWLX6N	ABCA8_HUMAN	Decreases Expression	[13]
ATP-binding cassette sub-family C member 6 (ABCC6)	OTZT0LKT	MRP6_HUMAN	Decreases Expression	[13]
Ornithine transcarbamylase, mitochondrial (OTC)	OTJ57GGA	OTC_HUMAN	Decreases Expression	[13]
Coagulation factor X (F10)	OT2BLK17	FA10_HUMAN	Decreases Expression	[13]
Coagulation factor XII (F12)	OTBFD2FU	FA12_HUMAN	Decreases Expression	[13]
Complement factor B (CFB)	OTZITNEJ	CFAB_HUMAN	Decreases Expression	[13]
Serine protease inhibitor Kazal-type 1 (SPINK1)	OTSUVAL2	ISK1_HUMAN	Increases Expression	[13]
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)	OT7KZMP2	DRA_HUMAN	Decreases Expression	[13]
Plasma kallikrein (KLKB1)	OTGSEISX	KLKB1_HUMAN	Decreases Expression	[13]
Vitamin K-dependent protein C (PROC)	OTGVH484	PROC_HUMAN	Decreases Expression	[13]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[13]
Glycophorin-C (GYPC)	OTOEDR7O	GLPC_HUMAN	Increases Expression	[13]
Fructose-bisphosphate aldolase B (ALDOB)	OT7FR69A	ALDOB_HUMAN	Decreases Expression	[13]
Arginase-1 (ARG1)	OTHZITAM	ARGI1_HUMAN	Decreases Expression	[13]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Expression	[13]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Decreases Expression	[13]
Serine protease hepsin (HPN)	OT7QNA61	HEPS_HUMAN	Decreases Expression	[13]
Tyrosine-protein kinase Fyn (FYN)	OTLSLVZS	FYN_HUMAN	Decreases Expression	[13]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Decreases Expression	[13]
Apolipoprotein A-IV (APOA4)	OT466POQ	APOA4_HUMAN	Decreases Expression	[13]
Asialoglycoprotein receptor 2 (ASGR2)	OTFSGOVY	ASGR2_HUMAN	Decreases Expression	[13]
Complement component C8 alpha chain (C8A)	OTIJ65J4	CO8A_HUMAN	Decreases Expression	[13]
Complement component C8 beta chain (C8B)	OTGDJJOK	CO8B_HUMAN	Decreases Expression	[13]
Complement component C8 gamma chain (C8G)	OTZM027I	CO8G_HUMAN	Decreases Expression	[13]
All-trans-retinol dehydrogenase ADH4 (ADH4)	OTKDKKNG	ADH4_HUMAN	Decreases Expression	[13]
Complement factor H (CFH)	OTAGKQTJ	CFAH_HUMAN	Decreases Expression	[13]
Coagulation factor VII (F7)	OTGNJ97M	FA7_HUMAN	Decreases Expression	[13]
Mannose-binding protein C (MBL2)	OTS63HG5	MBL2_HUMAN	Increases Expression	[13]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Decreases Expression	[13]
Nucleoprotein TPR (TPR)	OTUBBA4W	TPR_HUMAN	Decreases Expression	[13]
5-aminolevulinate synthase, non-specific, mitochondrial (ALAS1)	OTQY6ZSF	HEM1_HUMAN	Increases Expression	[13]
D-amino-acid oxidase (DAO)	OTZFVRIN	OXDA_HUMAN	Decreases Expression	[13]
Carboxypeptidase N catalytic chain (CPN1)	OTKXIFI6	CBPN_HUMAN	Decreases Expression	[13]
Beta-galactoside alpha-2,6-sialyltransferase 1 (ST6GAL1)	OT7US3NO	SIAT1_HUMAN	Decreases Expression	[13]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1 (PFKFB1)	OTTHX4NB	F261_HUMAN	Decreases Expression	[13]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Increases Expression	[13]
Insulin-like growth factor-binding protein 2 (IGFBP2)	OTG1P60E	IBP2_HUMAN	Decreases Expression	[13]
Cytochrome P450 2A7 (CYP2A7)	OTRJ3P2Z	CP2A7_HUMAN	Decreases Expression	[13]
5'-nucleotidase (NT5E)	OT7J5LT6	5NTD_HUMAN	Decreases Expression	[13]
Sterol carrier protein 2 (SCP2)	OTPAFCPQ	SCP2_HUMAN	Decreases Expression	[13]
Fibroblast growth factor receptor 3 (FGFR3)	OTSAXDIL	FGFR3_HUMAN	Decreases Expression	[13]
Cytochrome P450 7A1 (CYP7A1)	OT8Z5KLD	CP7A1_HUMAN	Decreases Expression	[13]
Arylacetamide deacetylase (AADAC)	OT8VACT2	AAAD_HUMAN	Increases Expression	[13]
Vitamin K-dependent protein Z (PROZ)	OTI3TXBE	PROZ_HUMAN	Decreases Expression	[13]
Receptor-type tyrosine-protein phosphatase epsilon (PTPRE)	OTOD5NID	PTPRE_HUMAN	Increases Expression	[13]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4)	OTMWFDAC	AT2B4_HUMAN	Increases Expression	[13]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Decreases Expression	[13]
Serum paraoxonase/arylesterase 1 (PON1)	OTD0Z2XO	PON1_HUMAN	Decreases Expression	[13]
G0/G1 switch protein 2 (G0S2)	OT8FL49L	G0S2_HUMAN	Decreases Expression	[13]
Alcohol dehydrogenase 6 (ADH6)	OTS7DYH9	ADH6_HUMAN	Decreases Expression	[13]
Proprotein convertase subtilisin/kexin type 6 (PCSK6)	OTI64BU4	PCSK6_HUMAN	Decreases Expression	[13]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Decreases Expression	[13]
Kallistatin (SERPINA4)	OTBK0GG7	KAIN_HUMAN	Decreases Expression	[13]
D-dopachrome decarboxylase (DDT)	OTF5HTYL	DOPD_HUMAN	Decreases Expression	[13]
GTP cyclohydrolase 1 feedback regulatory protein (GCHFR)	OTEOT8GI	GFRP_HUMAN	Decreases Expression	[13]
Pyruvate kinase PKLR (PKLR)	OTTTM1QI	KPYR_HUMAN	Decreases Expression	[13]
Carbamoyl-phosphate synthase , mitochondrial (CPS1)	OTXV8NSR	CPSM_HUMAN	Decreases Expression	[13]
Cystathionine gamma-lyase (CTH)	OTC90LA0	CGL_HUMAN	Decreases Expression	[13]
CD70 antigen (CD70)	OTHB2AL1	CD70_HUMAN	Increases Expression	[13]
Cytochrome P450 2C18 (CYP2C18)	OTY687L9	CP2CI_HUMAN	Decreases Expression	[13]
Carbonic anhydrase 5A, mitochondrial (CA5A)	OTP9M7VW	CAH5A_HUMAN	Decreases Expression	[13]
Nuclear receptor ROR-alpha (RORA)	OTGQT12P	RORA_HUMAN	Decreases Expression	[13]
Cystathionine beta-synthase (CBS)	OT46FSKD	CBS_HUMAN	Decreases Expression	[13]
Glucose-6-phosphatase catalytic subunit 1 (G6PC1)	OTJ6FM9F	G6PC1_HUMAN	Decreases Expression	[13]
Pigment epithelium-derived factor (SERPINF1)	OTWZH98J	PEDF_HUMAN	Decreases Expression	[13]
Isoleucine--tRNA ligase, cytoplasmic (IARS1)	OT9WXH5N	SYIC_HUMAN	Increases Expression	[13]
Afamin (AFM)	OTPOR8IO	AFAM_HUMAN	Decreases Expression	[13]
5-hydroxytryptamine receptor 3A (HTR3A)	OTAIV1AK	5HT3A_HUMAN	Increases Expression	[13]
Glutamate--cysteine ligase regulatory subunit (GCLM)	OT6CP234	GSH0_HUMAN	Increases Expression	[13]
Flavin-containing monooxygenase 5 (FMO5)	OTTILF8T	FMO5_HUMAN	Decreases Expression	[13]
Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)	OTI862QH	CPT1A_HUMAN	Increases Expression	[13]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Increases Expression	[13]
Stanniocalcin-1 (STC1)	OTGVVXYF	STC1_HUMAN	Decreases Expression	[13]
Trifunctional enzyme subunit beta, mitochondrial (HADHB)	OT4Y1I62	ECHB_HUMAN	Increases Expression	[13]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Decreases Expression	[13]
Large ribosomal subunit protein eL15 (RPL15)	OT7Y42LL	RL15_HUMAN	Increases Expression	[13]
Protein BTG1 (BTG1)	OTVJ2CDM	BTG1_HUMAN	Decreases Expression	[13]
Estrogen-related receptor gamma (ESRRG)	OTC3A0KU	ERR3_HUMAN	Decreases Expression	[13]
Cytochrome P450 4F2 (CYP4F2)	OTKILAER	CP4F2_HUMAN	Decreases Expression	[13]
T-complex protein 1 subunit beta (CCT2)	OTW1VV4E	TCPB_HUMAN	Increases Expression	[13]
Sushi repeat-containing protein SRPX (SRPX)	OT5B9LXS	SRPX_HUMAN	Increases Expression	[13]
4-aminobutyrate aminotransferase, mitochondrial (ABAT)	OTXAGR7J	GABT_HUMAN	Decreases Expression	[13]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2)	OTQR5SXD	CX6A2_HUMAN	Decreases Expression	[13]
Aminoacylase-1 (ACY1)	OT9WU7X3	ACY1_HUMAN	Decreases Expression	[13]
Transcription factor SOX-4 (SOX4)	OTSS40SS	SOX4_HUMAN	Increases Expression	[13]
Follistatin-related protein 1 (FSTL1)	OT6KEZUD	FSTL1_HUMAN	Increases Expression	[13]
Secreted phosphoprotein 24 (SPP2)	OTX254AR	SPP24_HUMAN	Decreases Expression	[13]
Syntaxin-3 (STX3)	OT4CIWLJ	STX3_HUMAN	Increases Expression	[13]
Protein phosphatase 1 regulatory subunit 1A (PPP1R1A)	OTGTAGCV	PPR1A_HUMAN	Decreases Expression	[13]
Dihydropyrimidinase (DPYS)	OTLTUIVL	DPYS_HUMAN	Decreases Expression	[13]
SPARC-like protein 1 (SPARCL1)	OT74DWMV	SPRL1_HUMAN	Decreases Expression	[13]
Laminin subunit alpha-4 (LAMA4)	OTHI7TA0	LAMA4_HUMAN	Increases Expression	[13]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Increases Expression	[13]
Hydroxyacylglutathione hydrolase, mitochondrial (HAGH)	OTYMDAYV	GLO2_HUMAN	Decreases Expression	[13]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2)	OTJ8LX4N	PCKGM_HUMAN	Decreases Expression	[13]
BTB/POZ domain-containing protein 16 (BTBD16)	OT04G9HG	BTBDG_HUMAN	Decreases Expression	[13]
Triokinase/FMN cyclase (TKFC)	OTTWXIOI	TKFC_HUMAN	Decreases Expression	[13]
Ectonucleoside triphosphate diphosphohydrolase 8 (ENTPD8)	OTB9GJ1V	ENTP8_HUMAN	Decreases Expression	[13]
Kidney mitochondrial carrier protein 1 (SLC25A30)	OT2VA5PI	KMCP1_HUMAN	Increases Expression	[13]
Early estrogen-induced gene 1 protein (EEIG1)	OT2BMEAE	EEIG1_HUMAN	Increases Expression	[13]
Solute carrier family 22 member 10 (SLC22A10)	OTUVJI3H	S22AA_HUMAN	Decreases Expression	[13]
Acyl-coenzyme A synthetase ACSM5, mitochondrial (ACSM5)	OTWMDQPX	ACSM5_HUMAN	Decreases Expression	[13]
Iodotyrosine deiodinase 1 (IYD)	OT8BQWTE	IYD1_HUMAN	Decreases Expression	[13]
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 4 (LINGO4)	OTLADERJ	LIGO4_HUMAN	Decreases Expression	[13]
Alkylglycerol monooxygenase (AGMO)	OTGMAHAT	ALKMO_HUMAN	Decreases Expression	[13]
Ras and Rab interactor-like protein (RINL)	OTZ0NDKE	RINL_HUMAN	Increases Expression	[13]
Hemojuvelin (HJV)	OT4235J2	RGMC_HUMAN	Decreases Expression	[13]
Mitochondrial S-adenosylmethionine carrier protein (SLC25A26)	OTSF2NXD	SAMC_HUMAN	Increases Expression	[13]
Equilibrative nucleoside transporter 4 (SLC29A4)	OTWTZXMX	S29A4_HUMAN	Increases Expression	[13]
Transient receptor potential cation channel subfamily M member 8 (TRPM8)	OT7ACGYK	TRPM8_HUMAN	Increases Expression	[13]
L-xylulose reductase (DCXR)	OTYVXRXB	DCXR_HUMAN	Decreases Expression	[13]
Organic solute transporter subunit alpha (SLC51A)	OTDJRZ0P	OSTA_HUMAN	Decreases Expression	[13]
Organic solute transporter subunit beta (SLC51B)	OT4WYPSR	OSTB_HUMAN	Increases Expression	[13]
2-acylglycerol O-acyltransferase 3 (MOGAT3)	OTPGLUBS	MOGT3_HUMAN	Decreases Expression	[13]
Src kinase-associated phosphoprotein 1 (SKAP1)	OTD4ZKAL	SKAP1_HUMAN	Decreases Expression	[13]
Cell division cycle protein 20 homolog B (CDC20B)	OTO5F8CF	CD20B_HUMAN	Decreases Expression	[13]
Transmembrane protease serine 6 (TMPRSS6)	OTA17R1M	TMPS6_HUMAN	Decreases Expression	[13]
Organic anion transporter 7 (SLC22A9)	OTO4BJCC	S22A9_HUMAN	Decreases Expression	[13]
Volume-regulated anion channel subunit LRRC8A (LRRC8A)	OT23OE7H	LRC8A_HUMAN	Decreases Expression	[13]
Tumor protein p53-inducible nuclear protein 2 (TP53INP2)	OT0GTBXO	T53I2_HUMAN	Decreases Expression	[13]
Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 (PPIL6)	OTOZQMQE	PPIL6_HUMAN	Increases Expression	[13]
NADH dehydrogenase 1 alpha subcomplex assembly factor 2 (NDUFAF2)	OTC8QPRS	NDUF2_HUMAN	Increases Expression	[13]
Lysoplasmalogenase TMEM86B (TMEM86B)	OTOKL8BF	TM86B_HUMAN	Decreases Expression	[13]
Interleukin-22 receptor subunit alpha-1 (IL22RA1)	OTGVKLBR	I22R1_HUMAN	Decreases Expression	[13]
Sodium-dependent lysophosphatidylcholine symporter 1 (MFSD2A)	OTVG1VG0	NLS1_HUMAN	Decreases Expression	[13]
Mixed lineage kinase domain-like protein (MLKL)	OTDSLC81	MLKL_HUMAN	Increases Expression	[13]
Clarin-3 (CLRN3)	OTZDNL65	CLRN3_HUMAN	Decreases Expression	[13]
Phosphatidylinositol 4-kinase type 2-beta (PI4K2B)	OT0D51QP	P4K2B_HUMAN	Decreases Expression	[13]
Serine/threonine-protein kinase BRSK1 (BRSK1)	OT6N35Q0	BRSK1_HUMAN	Decreases Expression	[13]
Transmembrane protein 171 (TMEM171)	OTJPHOWW	TM171_HUMAN	Increases Expression	[13]
Thyroid hormone-inducible hepatic protein (THRSP)	OTKYE01L	THRSP_HUMAN	Decreases Expression	[13]
Retinol dehydrogenase 5 (RDH5)	OTYBZHCC	RDH5_HUMAN	Decreases Expression	[13]
ATP-binding cassette sub-family C member 2 (ABCC2)	OTJSIGV5	MRP2_HUMAN	Increases Expression	[13]
Proteoglycan 4 (PRG4)	OT34NR3N	PRG4_HUMAN	Decreases Expression	[13]
Solute carrier organic anion transporter family member 2A1 (SLCO2A1)	OT3062CA	SO2A1_HUMAN	Increases Expression	[13]
Liver-expressed antimicrobial peptide 2 (LEAP2)	OTUOPIS5	LEAP2_HUMAN	Decreases Expression	[13]
Interferon-stimulated gene 20 kDa protein (ISG20)	OTCWRJJW	ISG20_HUMAN	Decreases Expression	[13]
GTP-binding protein Rhes (RASD2)	OTETA815	RHES_HUMAN	Increases Expression	[13]
FXYD domain-containing ion transport regulator 5 (FXYD5)	OT81DIOD	FXYD5_HUMAN	Increases Expression	[13]
Endoplasmic reticulum resident protein 27 (ERP27)	OTVMGE2H	ERP27_HUMAN	Decreases Expression	[13]
E3 ubiquitin-protein ligase RNF125 (RNF125)	OTBD1Q3X	RN125_HUMAN	Decreases Expression	[13]
Uncharacterized protein C11orf24 (C11ORF24)	OT2DOJ6E	CK024_HUMAN	Decreases Expression	[13]
Calmodulin-like protein 4 (CALML4)	OT6DD5EW	CALL4_HUMAN	Decreases Expression	[13]
Transmembrane protein 41A (TMEM41A)	OTAAULKY	TM41A_HUMAN	Decreases Expression	[13]
SH2 domain-containing adapter protein D (SHD)	OTGTHL5V	SHD_HUMAN	Decreases Expression	[13]
Membrane-spanning 4-domains subfamily A member 10 (MS4A10)	OTH3LAUX	M4A10_HUMAN	Decreases Expression	[13]
Serine protease FAM111A (FAM111A)	OTVLARLG	F111A_HUMAN	Decreases Expression	[13]
Tribbles homolog 3 (TRIB3)	OTG5OS7X	TRIB3_HUMAN	Decreases Expression	[13]
Serine incorporator 2 (SERINC2)	OTZ039U0	SERC2_HUMAN	Increases Expression	[13]
G-protein coupled estrogen receptor 1 (GPER1)	OTUK0TDC	GPER1_HUMAN	Decreases Expression	[13]
Sodium-coupled neutral amino acid transporter 3 (SLC38A3)	OTCHH25G	S38A3_HUMAN	Decreases Expression	[13]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1)	OTU230MC	ISCA1_HUMAN	Increases Expression	[13]
Guanine nucleotide-binding protein-like 3 (GNL3)	OTILGYO4	GNL3_HUMAN	Increases Expression	[13]
Group XIIB secretory phospholipase A2-like protein (PLA2G12B)	OTY7GXA6	PG12B_HUMAN	Decreases Expression	[13]
Angiopoietin-related protein 4 (ANGPTL4)	OTQL5SPX	ANGL4_HUMAN	Increases Expression	[13]
Sulfiredoxin-1 (SRXN1)	OTYDBO4L	SRXN1_HUMAN	Increases Expression	[13]
Alanine--glyoxylate aminotransferase 2, mitochondrial (AGXT2)	OTO6QUTM	AGT2_HUMAN	Decreases Expression	[13]
Transmembrane 6 superfamily member 2 (TM6SF2)	OTXMU5ZV	TM6S2_HUMAN	Decreases Expression	[13]
DNA-directed RNA polymerase I subunit RPA49 (POLR1E)	OTCBMKW6	RPA49_HUMAN	Increases Expression	[13]
Cytosolic beta-glucosidase (GBA3)	OT86XWU2	GBA3_HUMAN	Decreases Expression	[13]
2-aminomuconic semialdehyde dehydrogenase (ALDH8A1)	OTINY3MW	AL8A1_HUMAN	Decreases Expression	[13]
Mid1-interacting protein 1 (MID1IP1)	OTFCORJM	M1IP1_HUMAN	Decreases Expression	[13]
NADPH oxidase 4 (NOX4)	OTTYQ097	NOX4_HUMAN	Decreases Expression	[13]
PI-PLC X domain-containing protein 1 (PLCXD1)	OTU7KCQL	PLCX1_HUMAN	Decreases Expression	[13]
Ethanolamine kinase 2 (ETNK2)	OT5S1Z75	EKI2_HUMAN	Decreases Expression	[13]
Spermatogenesis- and oogenesis-specific basic helix-loop-helix-containing protein 2 (SOHLH2)	OTB9EM6C	SOLH2_HUMAN	Increases Expression	[13]
H/ACA ribonucleoprotein complex subunit 1 (GAR1)	OTA580RX	GAR1_HUMAN	Increases Expression	[13]
Cingulin (CGN)	OTBCQ8AQ	CING_HUMAN	Decreases Expression	[13]
Alpha-aminoadipic semialdehyde synthase, mitochondrial (AASS)	OTYCN07T	AASS_HUMAN	Decreases Expression	[13]
Lipid transferase CIDEB (CIDEB)	OT873IYM	CIDEB_HUMAN	Decreases Expression	[13]
Annexin A10 (ANXA10)	OTA8LWSL	ANX10_HUMAN	Decreases Expression	[13]
Transcription factor SOX-13 (SOX13)	OTCIF6KC	SOX13_HUMAN	Decreases Expression	[13]
Microtubule-associated protein RP/EB family member 3 (MAPRE3)	OTSCLETV	MARE3_HUMAN	Increases Expression	[13]
Regulating synaptic membrane exocytosis protein 2 (RIMS2)	OTQASWDH	RIMS2_HUMAN	Decreases Expression	[13]
Protein phosphatase 1 regulatory subunit 3C (PPP1R3C)	OTEU05TX	PPR3C_HUMAN	Decreases Expression	[13]
Endothelial lipase (LIPG)	OTHEE942	LIPG_HUMAN	Decreases Expression	[13]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Increases Expression	[13]
Solute carrier family 22 member 7 (SLC22A7)	OTKTNH1W	S22A7_HUMAN	Decreases Expression	[13]
Agouti-related protein (AGRP)	OT7XRHWU	AGRP_HUMAN	Increases Expression	[14]
Golgi integral membrane protein 4 (GOLIM4)	OTB5NV8A	GOLI4_HUMAN	Decreases Expression	[14]
Long-chain fatty acid transport protein 2 (SLC27A2)	OT7JEG5F	S27A2_HUMAN	Decreases Expression	[14]
Rho guanine nucleotide exchange factor 10 (ARHGEF10)	OTHJ1Y4I	ARHGA_HUMAN	Decreases Expression	[14]
Secretory carrier-associated membrane protein 1 (SCAMP1)	OTFS4IKJ	SCAM1_HUMAN	Increases Expression	[14]
Protein phosphatase 1D (PPM1D)	OT8NLZ9D	PPM1D_HUMAN	Increases Expression	[14]
Cochlin (COCH)	OTBEHD89	COCH_HUMAN	Decreases Expression	[14]
Mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20)	OT6CLFXB	MCAT_HUMAN	Decreases Expression	[14]
NUAK family SNF1-like kinase 1 (NUAK1)	OTLLHJJQ	NUAK1_HUMAN	Decreases Expression	[14]
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IB (MAN1A2)	OTITCN3Q	MA1A2_HUMAN	Decreases Expression	[14]
E3 ubiquitin-protein ligase listerin (LTN1)	OTIW2HTX	LTN1_HUMAN	Decreases Expression	[14]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1)	OTERJ4VQ	SO2B1_HUMAN	Decreases Expression	[14]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[14]
Tyrosine-protein kinase Fgr (FGR)	OTCUYU9F	FGR_HUMAN	Increases Expression	[14]
RNA-binding protein RO60 (RO60)	OTLGM5A8	RO60_HUMAN	Decreases Expression	[14]
Fos-related antigen 1 (FOSL1)	OT9YTYMB	FOSL1_HUMAN	Increases Expression	[14]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3)	OTC1UOHP	ATF3_HUMAN	Increases Expression	[14]
Retinoic acid receptor RXR-alpha (RXRA)	OTP1TBDM	RXRA_HUMAN	Decreases Expression	[14]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)	OTDRV63V	GA45A_HUMAN	Increases Expression	[14]
ETS domain-containing protein Elk-4 (ELK4)	OTVSSEOE	ELK4_HUMAN	Increases Expression	[14]
DNA damage-inducible transcript 3 protein (DDIT3)	OTI8YKKE	DDIT3_HUMAN	Increases Expression	[14]
Serine/threonine-protein kinase SIK1 (SIK1)	OT6FCHME	SIK1_HUMAN	Increases Expression	[14]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Decreases Expression	[14]
E3 ubiquitin-protein ligase Mdm2 (MDM2)	OTOVXARF	MDM2_HUMAN	Increases Expression	[14]
Adenylate cyclase type 1 (ADCY1)	OTSLLFZO	ADCY1_HUMAN	Decreases Expression	[14]
Zinc finger protein Rlf (RLF)	OTCSPZVK	RLF_HUMAN	Increases Expression	[14]
Kelch-like ECH-associated protein 1 (KEAP1)	OTFHOD0C	KEAP1_HUMAN	Increases Expression	[14]
Src substrate cortactin (CTTN)	OTJRG4ES	SRC8_HUMAN	Decreases Expression	[14]
Enhancer of filamentation 1 (NEDD9)	OTGCFN4M	CASL_HUMAN	Decreases Expression	[14]
Protein disulfide-isomerase A5 (PDIA5)	OT76ZSX5	PDIA5_HUMAN	Decreases Expression	[14]
Neuronal regeneration-related protein (NREP)	OT2AZPKK	NREP_HUMAN	Decreases Expression	[14]
Dual specificity protein phosphatase 5 (DUSP5)	OTH96RA7	DUS5_HUMAN	Increases Expression	[14]
Atos homolog protein A (ATOSA)	OTWFM5G0	ATOSA_HUMAN	Decreases Expression	[14]
Glycerol-3-phosphate acyltransferase 3 (GPAT3)	OTJUGPK0	GPAT3_HUMAN	Increases Expression	[14]
Ribosomal protein eS27-like (RPS27L)	OTZWHU0N	RS27L_HUMAN	Decreases Expression	[14]
Protein mono-ADP-ribosyltransferase TIPARP (TIPARP)	OTZ4BG4B	PARPT_HUMAN	Increases Expression	[14]
Extracellular sulfatase Sulf-2 (SULF2)	OTIXMUVL	SULF2_HUMAN	Decreases Expression	[14]
SH3 domain and tetratricopeptide repeat-containing protein 1 (SH3TC1)	OT0HYZIU	S3TC1_HUMAN	Increases Expression	[14]
Uncharacterized protein C4orf3 (C4ORF3)	OT6TFN1O	CD003_HUMAN	Decreases Expression	[14]
Sortilin-related receptor (SORL1)	OTQ8FFNS	SORL_HUMAN	Decreases Expression	[14]
GTP-binding protein Rit1 (RIT1)	OTVNOGOH	RIT1_HUMAN	Increases Expression	[14]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1)	OT2363Z9	T53I1_HUMAN	Decreases Expression	[14]
Protein orai-3 (ORAI3)	OTUP3OH3	ORAI3_HUMAN	Decreases Expression	[14]
Ectonucleoside triphosphate diphosphohydrolase 7 (ENTPD7)	OT3QER33	ENTP7_HUMAN	Decreases Expression	[14]
Oxidative stress-induced growth inhibitor 1 (OSGIN1)	OT9KIVZW	OSGI1_HUMAN	Increases Expression	[14]
Insulin-induced gene 2 protein (INSIG2)	OTX4VY51	INSI2_HUMAN	Decreases Expression	[14]
Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (ARFGEF2)	OTM3CQZT	BIG2_HUMAN	Increases Expression	[14]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Affects Localization	[39]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[39]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Increases Expression	[39]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Increases Expression	[40]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Decreases Expression	[41]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[42]
Neuropilin-1 (NRP1)	OTCGULYV	NRP1_HUMAN	Decreases Expression	[41]
Centrin-3 (CETN3)	OTG4PL7H	CETN3_HUMAN	Decreases Expression	[41]
Protein phosphatase 1G (PPM1G)	OTLZL9CG	PPM1G_HUMAN	Increases Expression	[41]
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Decreases Expression	[18]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[43]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[18]
Death effector domain-containing protein (DEDD)	OTIL349E	DEDD_HUMAN	Increases Expression	[41]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Increases Expression	[41]
STAM-binding protein (STAMBP)	OTOT2OXM	STABP_HUMAN	Decreases Expression	[41]
Centrosomal protein 43 (CEP43)	OT8TRHCF	CEP43_HUMAN	Decreases Expression	[41]
Cytochrome b5 (CYB5A)	OT6SN4RM	CYB5_HUMAN	Affects Expression	[15]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases Expression	[44]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Phosphorylation	[45]
Prothrombin (F2)	OTNFSM49	THRB_HUMAN	Affects Expression	[15]
Carbonic anhydrase 1 (CA1)	OTNFBVVQ	CAH1_HUMAN	Affects Expression	[15]
Carbonic anhydrase 2 (CA2)	OTJRMUAG	CAH2_HUMAN	Affects Expression	[15]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[46]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Decreases Expression	[47]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Expression	[48]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Increases Expression	[49]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Secretion	[50]
Interferon gamma (IFNG)	OTXG9JM7	IFNG_HUMAN	Affects Expression	[51]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Secretion	[52]
Alpha-crystallin B chain (CRYAB)	OTY4JGYU	CRYAB_HUMAN	Affects Expression	[15]
Prelamin-A/C (LMNA)	OT3SG7ZR	LMNA_HUMAN	Affects Expression	[15]
Fibrinogen gamma chain (FGG)	OT5BJSEX	FIBG_HUMAN	Affects Expression	[15]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[53]
Fibronectin (FN1)	OTB5ZN4Q	FINC_HUMAN	Decreases Expression	[54]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Affects Expression	[15]
Ferritin light chain (FTL)	OTYQA8A6	FRIL_HUMAN	Affects Expression	[15]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Affects Expression	[15]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Expression	[55]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Decreases Expression	[56]
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)	OTBPMIMW	G3P_HUMAN	Affects Expression	[15]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Expression	[41]
Heat shock protein beta-1 (HSPB1)	OTHFZ8ED	HSPB1_HUMAN	Affects Expression	[15]
Insulin-like growth factor I (IGF1)	OTIIZR61	IGF1_HUMAN	Decreases Secretion	[57]
Integrin beta-3 (ITGB3)	OTWCK1K6	ITB3_HUMAN	Affects Expression	[15]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Affects Expression	[51]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Decreases Expression	[58]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Expression	[59]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[60]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Increases Expression	[61]
Beta-casein (CSN2)	OT22C0PD	CASB_HUMAN	Increases Expression	[62]
Insulin receptor (INSR)	OTTY341H	INSR_HUMAN	Increases Phosphorylation	[63]
Gelsolin (GSN)	OT4KS2UU	GELS_HUMAN	Increases Expression	[64]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Phosphorylation	[65]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Decreases Expression	[66]
Alpha-enolase (ENO1)	OTB1KWJS	ENOA_HUMAN	Affects Expression	[15]
Tropomyosin alpha-3 chain (TPM3)	OT5RU5G6	TPM3_HUMAN	Decreases Expression	[67]
Lipoprotein lipase (LPL)	OTTW0267	LIPL_HUMAN	Increases Expression	[68]
Protein disulfide-isomerase (P4HB)	OTTYNYPF	PDIA1_HUMAN	Affects Expression	[15]
Annexin A2 (ANXA2)	OTFNS0CC	ANXA2_HUMAN	Affects Expression	[15]
Transcription factor Sp1 (SP1)	OTISPT4X	SP1_HUMAN	Decreases Expression	[54]
Integrin alpha-IIb (ITGA2B)	OT4Y17PY	ITA2B_HUMAN	Affects Expression	[15]
Integrin alpha-5 (ITGA5)	OT3RCI67	ITA5_HUMAN	Increases Expression	[18]
Galectin-1 (LGALS1)	OT8LDFWR	LEG1_HUMAN	Affects Expression	[15]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Decreases Expression	[69]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[70]
Endoplasmic reticulum chaperone BiP (HSPA5)	OTFUIRAO	BIP_HUMAN	Increases Expression	[71]
Hepatic triacylglycerol lipase (LIPC)	OTZY5SC9	LIPC_HUMAN	Increases Expression	[47]
Lysosome-associated membrane glycoprotein 1 (LAMP1)	OTYE92QY	LAMP1_HUMAN	Increases Expression	[65]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Increases Expression	[41]
Proliferating cell nuclear antigen (PCNA)	OTHZ1RIA	PCNA_HUMAN	Decreases Expression	[72]
Collagen alpha-1(VI) chain (COL6A1)	OTYKSCOB	CO6A1_HUMAN	Affects Expression	[15]
Collagen alpha-2(VI) chain (COL6A2)	OTQC6PPO	CO6A2_HUMAN	Affects Expression	[15]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[64]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Decreases Response To Substance	[73]
Beta-3 adrenergic receptor (ADRB3)	OTPMG4V7	ADRB3_HUMAN	Decreases Expression	[74]
Hepatocyte growth factor (HGF)	OTGHUA23	HGF_HUMAN	Increases Expression	[75]
Nidogen-1 (NID1)	OTKLBLS6	NID1_HUMAN	Affects Expression	[15]
Endoplasmin (HSP90B1)	OT02XLBR	ENPL_HUMAN	Affects Expression	[15]
G2/mitotic-specific cyclin-B1 (CCNB1)	OT19S7E5	CCNB1_HUMAN	Decreases Expression	[76]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4)	OTJZG0LD	GLUT4_HUMAN	Increases Expression	[77]
Insulin-degrading enzyme (IDE)	OT5GQTJ5	IDE_HUMAN	Increases Expression	[78]
Fatty acid-binding protein, adipocyte (FABP4)	OT3DKFOU	FABP4_HUMAN	Increases Expression	[79]
P-selectin (SELP)	OTWR90PK	LYAM3_HUMAN	Decreases Expression	[80]
Cyclic AMP-responsive element-binding protein 1 (CREB1)	OT1MDLA1	CREB1_HUMAN	Decreases Phosphorylation	[54]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[81]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3)	OTA6HYBA	GBB3_HUMAN	Affects Expression	[15]
E-selectin (SELE)	OT33RZWY	LYAM2_HUMAN	Decreases Expression	[53]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2)	OTPGAU0U	AT2A2_HUMAN	Increases Expression	[82]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Increases Expression	[83]
Neutrophil cytosol factor 2 (NCF2)	OTAUW7L2	NCF2_HUMAN	Decreases Expression	[84]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[76]
Filamin-A (FLNA)	OTYZ9JXM	FLNA_HUMAN	Affects Expression	[15]
Thromboxane A2 receptor (TBXA2R)	OT9CIHQ5	TA2R_HUMAN	Decreases Expression	[85]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Expression	[86]
Ribosomal protein S6 kinase beta-1 (RPS6KB1)	OTAELNGX	KS6B1_HUMAN	Decreases Phosphorylation	[87]
G1/S-specific cyclin-D1 (CCND1)	OT8HPTKJ	CCND1_HUMAN	Decreases Expression	[64]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[88]
Cyclin-C (CCNC)	OTMVK4K4	CCNC_HUMAN	Decreases Expression	[41]
G1/S-specific cyclin-E1 (CCNE1)	OTLD7UID	CCNE1_HUMAN	Decreases Expression	[76]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Decreases Expression	[76]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[64]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Decreases Phosphorylation	[69]
Moesin (MSN)	OTZJ4J6G	MOES_HUMAN	Affects Expression	[15]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[89]
Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1)	OT5BZ1J9	P85A_HUMAN	Increases Expression	[17]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[89]
Retinoic acid receptor RXR-beta (RXRB)	OTNPDXG2	RXRB_HUMAN	Affects Binding	[90]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Increases Phosphorylation	[91]
Protein disulfide-isomerase A3 (PDIA3)	OTHPQ0Q3	PDIA3_HUMAN	Affects Expression	[15]
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform (PPP2R1A)	OTYA3GB4	2AAA_HUMAN	Increases Expression	[41]
G1/S-specific cyclin-D2 (CCND2)	OTDULQF9	CCND2_HUMAN	Decreases Expression	[72]
G1/S-specific cyclin-D3 (CCND3)	OTNKPQ22	CCND3_HUMAN	Decreases Expression	[76]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[92]
Peroxiredoxin-2 (PRDX2)	OTLWCY9T	PRDX2_HUMAN	Affects Expression	[15]
C-C chemokine receptor type 7 (CCR7)	OTHFUOYE	CCR7_HUMAN	Decreases Expression	[93]
T-lymphocyte activation antigen CD80 (CD80)	OTJBLUQE	CD80_HUMAN	Decreases Expression	[93]
Polycomb complex protein BMI-1 (BMI1)	OTROVLJ0	BMI1_HUMAN	Decreases Expression	[81]
Nitric oxide synthase, inducible (NOS2)	OTKKIOJ1	NOS2_HUMAN	Decreases Expression	[52]
Prostaglandin G/H synthase 2 (PTGS2)	OT75U9M4	PGH2_HUMAN	Decreases Expression	[94]
Phosphoenolpyruvate carboxykinase, cytosolic (PCK1)	OTNWEJ5Y	PCKGC_HUMAN	Increases Expression	[95]
Insulin receptor substrate 1 (IRS1)	OTNO82CU	IRS1_HUMAN	Increases Phosphorylation	[63]
Myosin-9 (MYH9)	OT94Z706	MYH9_HUMAN	Affects Expression	[15]
Tumor necrosis factor receptor superfamily member 3 (LTBR)	OT2HVZGV	TNR3_HUMAN	Increases Expression	[41]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Increases Expression	[62]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Decreases Expression	[52]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Increases Expression	[41]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Decreases Expression	[17]
Neuroblastoma suppressor of tumorigenicity 1 (NBL1)	OTT37U4O	NBL1_HUMAN	Increases Expression	[41]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Increases Expression	[93]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Decreases Expression	[41]
Nicotinamide phosphoribosyltransferase (NAMPT)	OTVJR3GL	NAMPT_HUMAN	Affects Expression	[96]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)	OT1H0ZXC	ACHA4_HUMAN	Decreases Expression	[89]
ATP-binding cassette sub-family G member 1 (ABCG1)	OT5BG6MK	ABCG1_HUMAN	Increases Expression	[97]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[81]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[72]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Decreases Response To Substance	[73]
Retinoic acid receptor RXR-gamma (RXRG)	OT254B09	RXRG_HUMAN	Affects Binding	[90]
CX3C chemokine receptor 1 (CX3CR1)	OTIM9XT8	CX3C1_HUMAN	Decreases Expression	[98]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[62]
Caspase-4 (CASP4)	OTVQTV1L	CASP4_HUMAN	Decreases Expression	[41]
Steroidogenic acute regulatory protein, mitochondrial (STAR)	OTFEZ5AI	STAR_HUMAN	Increases Expression	[50]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[99]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2)	OTAKUO27	ACOT2_HUMAN	Increases Expression	[44]
Tuberin (TSC2)	OT47LWI9	TSC2_HUMAN	Increases Phosphorylation	[87]
Glycogen synthase kinase-3 beta (GSK3B)	OTL3L14B	GSK3B_HUMAN	Increases Phosphorylation	[100]
Cyclin-dependent kinase 7 (CDK7)	OTAO19PQ	CDK7_HUMAN	Decreases Expression	[41]
Death-associated protein 1 (DAP)	OT5YLL7E	DAP1_HUMAN	Increases Expression	[41]
Small ribosomal subunit protein mS29 (DAP3)	OTNPEZYM	RT29_HUMAN	Decreases Expression	[41]
Caveolin-2 (CAV2)	OT1FGRQX	CAV2_HUMAN	Increases Expression	[62]
Hexokinase-2 (HK2)	OTC0GCQO	HXK2_HUMAN	Increases Expression	[101]
Microsomal triglyceride transfer protein large subunit (MTTP)	OTNUVSDT	MTP_HUMAN	Increases Expression	[44]
Caspase-9 (CASP9)	OTD4RFFG	CASP9_HUMAN	Increases Activity	[102]
Laminin subunit beta-2 (LAMB2)	OT71OI2Y	LAMB2_HUMAN	Affects Expression	[15]
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)	OTOWDUNT	PTEN_HUMAN	Increases Expression	[103]
GTP-binding nuclear protein Ran (RAN)	OT2TER5M	RAN_HUMAN	Decreases Expression	[41]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 (GNB1)	OTLL7L74	GBB1_HUMAN	Affects Expression	[15]
Tropomyosin alpha-4 chain (TPM4)	OTN4YLYR	TPM4_HUMAN	Affects Expression	[15]
Fractalkine (CX3CL1)	OTPLGI0E	X3CL1_HUMAN	Affects Localization	[98]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Increases Activity	[104]
Protein delta homolog 1 (DLK1)	OTE1VLNB	DLK1_HUMAN	Decreases Expression	[105]
Fatty acid-binding protein 5 (FABP5)	OTNM186C	FABP5_HUMAN	Affects Expression	[15]
Caveolin-1 (CAV1)	OTEZUR1L	CAV1_HUMAN	Increases Expression	[106]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Increases Expression	[107]
Focal adhesion kinase 1 (PTK2)	OT3Q1JDY	FAK1_HUMAN	Decreases Phosphorylation	[108]
Hormone-sensitive lipase (LIPE)	OTMMVJ8A	LIPS_HUMAN	Increases Expression	[47]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[41]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Increases Expression	[41]
Peroxisome proliferator-activated receptor alpha (PPARA)	OTK095PP	PPARA_HUMAN	Affects Binding	[109]
Prolow-density lipoprotein receptor-related protein 1 (LRP1)	OTHTEH4G	LRP1_HUMAN	Increases Expression	[110]
Peroxisomal bifunctional enzyme (EHHADH)	OTBAAHL5	ECHP_HUMAN	Increases Expression	[44]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[106]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[111]
Runt-related transcription factor 2 (RUNX2)	OT97RQQM	RUNX2_HUMAN	Decreases Expression	[112]
Interleukin-18 (IL18)	OTBB2A8O	IL18_HUMAN	Decreases Expression	[59]
Beclin-1 (BECN1)	OT4X293M	BECN1_HUMAN	Increases Expression	[65]
LIM and SH3 domain protein 1 (LASP1)	OT2QIDCL	LASP1_HUMAN	Affects Expression	[15]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Expression	[44]
Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)	OTM0A0DY	ACOX1_HUMAN	Increases Expression	[47]
Mediator of RNA polymerase II transcription subunit 1 (MED1)	OTOO24C4	MED1_HUMAN	Affects Binding	[113]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[114]
Transcription factor E2F4 (E2F4)	OTB3JFH4	E2F4_HUMAN	Decreases Expression	[115]
Bcl-2 homologous antagonist/killer (BAK1)	OTDP6ILW	BAK_HUMAN	Increases Expression	[41]
kinase isozyme 4, mitochondrial (PDK4)	OTCMHMBZ	PDK4_HUMAN	Increases Expression	[101]
Caveolae-associated protein 1 (CAVIN1)	OTFO915U	CAVN1_HUMAN	Affects Expression	[15]
Long-chain fatty acid transport protein 1 (SLC27A1)	OTK03OZN	S27A1_HUMAN	Decreases Expression	[101]
Adiponectin receptor protein 2 (ADIPOR2)	OT2HDTL8	PAQR2_HUMAN	Increases Expression	[116]
Ferritin, mitochondrial (FTMT)	OTIUX6XG	FTMT_HUMAN	Affects Expression	[15]
Carnitine O-palmitoyltransferase 1, muscle isoform (CPT1B)	OTDNRW37	CPT1B_HUMAN	Increases Expression	[117]
Bcl2-associated agonist of cell death (BAD)	OT63ERYM	BAD_HUMAN	Increases Expression	[41]
Adiponectin receptor protein 1 (ADIPOR1)	OT65ZFZN	PAQR1_HUMAN	Affects Expression	[118]
Necdin (NDN)	OTYBYJ82	NECD_HUMAN	Increases Expression	[115]
Retinoic acid receptor responder protein 2 (RARRES2)	OT1BJE8K	RARR2_HUMAN	Decreases Expression	[119]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1)	OT50NR57	PINK1_HUMAN	Increases Expression	[120]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Decreases Expression	[43]
COMM domain-containing protein 5 (COMMD5)	OT6R7DXN	COMD5_HUMAN	Increases Expression	[121]
Ras-related protein Rab-1B (RAB1B)	OTAFCUAS	RAB1B_HUMAN	Increases Expression	[41]
Glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM)	OTR1XD9B	GPAT1_HUMAN	Increases Expression	[44]
Chorion-specific transcription factor GCMa (GCM1)	OT5CPAUT	GCM1_HUMAN	Increases Expression	[23]
Fibroblast growth factor 21 (FGF21)	OT3RXVRD	FGF21_HUMAN	Increases Expression	[122]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Increases Expression	[77]
Probable ATP-dependent RNA helicase DDX41 (DDX41)	OT6KEIHP	DDX41_HUMAN	Increases Expression	[41]
Cyclin-L1 (CCNL1)	OTAJSS3D	CCNL1_HUMAN	Decreases Expression	[41]
Anaphase-promoting complex subunit 10 (ANAPC10)	OTM03SME	APC10_HUMAN	Decreases Expression	[41]
Insulin receptor substrate 2 (IRS2)	OT46MJBE	IRS2_HUMAN	Increases Expression	[123]
Cytochrome P450 2C8 (CYP2C8)	OTHCWT42	CP2C8_HUMAN	Decreases Metabolism	[124]
Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)	OTK5T6HZ	NFAC2_HUMAN	Affects Response To Substance	[125]
Phosphatidate phosphatase LPIN1 (LPIN1)	OTQ75KF2	LPIN1_HUMAN	Increases Response To Substance	[126]

References

• [1] ClinicalTrials.gov (NCT02475499) Incretin-based Drugs and Pancreatic Cancer
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841).
• [3] Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3.
• [4] Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018 Nov;104(5):900-915.
• [5] Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet. 2007;46(2):93-108.
• [6] Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010 Dec;70(6):870-80.
• [7] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [8] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [9] Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicol In Vitro. 2015 Dec 25;30(1 Pt B):241-9.
• [10] Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
• [11] In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res. 2005 Apr;22(4):512-7. doi: 10.1007/s11095-005-2505-y. Epub 2005 Apr 7.
• [12] PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
• [13] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [14] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [15] Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
• [16] Rosiglitazone induces the unfolded protein response, but has no significant effect on cell viability, in monocytic and vascular smooth muscle cells. Biochem Biophys Res Commun. 2010 Oct 1;400(4):689-95. doi: 10.1016/j.bbrc.2010.08.129. Epub 2010 Sep 9.
• [17] Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun. 1999 Nov;265(1):265-71. doi: 10.1006/bbrc.1999.1657.
• [18] All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur J Haematol. 2009 Sep;83(3):191-202. doi: 10.1111/j.1600-0609.2009.01277.x. Epub 2009 May 8.
• [19] ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):231-43.
• [20] Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005 May;77(5):404-14.
• [21] Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 1999 Sep;48(3):424-32.
• [22] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [23] Regulation of the placental BCRP transporter by PPAR gamma. J Biochem Mol Toxicol. 2017 May;31(5):10.1002/jbt.21880. doi: 10.1002/jbt.21880. Epub 2016 Nov 23.
• [24] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [25] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [26] The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol. 2004 Aug;25(2):493-502.
• [27] Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
• [28] Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
• [29] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
• [30] Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 2007 Feb;92(2):720-4.
• [31] Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Mol Pharmacol. 2007 Sep;72(3):674-85.
• [32] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [33] Effects of PPAR-gamma agonist rosiglitazone on MMP-9 and TIMP-1 expression of monocyte-derived macrophages isolated from patients with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Aug;37(8):739-45.
• [34] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [35] Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs. ACS Med Chem Lett. 2011 Oct 15;3(1):39-42.
• [36] Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes. Drug Metab Dispos. 2013 Dec;41(12):2087-94.
• [37] PPARgama activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol. 2014 Mar;253:16-27.
• [38] Rosiglitazone inhibits chlorpyrifos-induced apoptosis via modulation of the oxidative stress and inflammatory response in SH-SY5Y cells. Toxicol Appl Pharmacol. 2014 Jul 15;278(2):159-71.
• [39] A comprehensive evaluation of anti-diabetic drugs on nuclear receptor PXR platform. Toxicol In Vitro. 2019 Oct;60:347-358.
• [40] Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes. 2005 May;54(5):1379-84. doi: 10.2337/diabetes.54.5.1379.
• [41] Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007 Jun;14(2):305-15. doi: 10.1677/ERC-06-0003.
• [42] Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med. 2008 Mar 15;44(6):1055-68. doi: 10.1016/j.freeradbiomed.2007.12.001. Epub 2007 Dec 8.
• [43] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [44] Replacement per- and polyfluoroalkyl substances (PFAS) are potent modulators of lipogenic and drug metabolizing gene expression signatures in primary human hepatocytes. Toxicol Appl Pharmacol. 2022 May 1;442:115991. doi: 10.1016/j.taap.2022.115991. Epub 2022 Mar 23.
• [45] Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Anticancer Res. 2008 Mar-Apr;28(2A):895-906.
• [46] [Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Mar;40(2):217-22.
• [47] In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res. 2012;2012:546548. doi: 10.1155/2012/546548. Epub 2012 Oct 22.
• [48] [Effect of Rosiglitazone on the proliferation and the production of transforming growth factor-beta 1 in cultured human Tenon' s capsule fibroblasts]. Zhonghua Yan Ke Za Zhi. 2008 May;44(5):413-7.
• [49] PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochem Biophys Res Commun. 2008 Feb 22;366(4):1096-101. doi: 10.1016/j.bbrc.2007.12.088. Epub 2007 Dec 26.
• [50] Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Reprod Biol Endocrinol. 2009 Dec 9;7:147. doi: 10.1186/1477-7827-7-147.
• [51] [Effect of rosiglitazone on the expression of T-bet/GATA-3 in T lymphocytes in patients with acute asthma]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):116-20.
• [52] The PPAR-dependent effect of flavonoid luteolin against damage induced by the chemotherapeutic irinotecan in human intestinal cells. Chem Biol Interact. 2022 Jan 5;351:109712. doi: 10.1016/j.cbi.2021.109712. Epub 2021 Oct 23.
• [53] Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1804-9. doi: 10.1161/01.ATV.0000176192.16951.9a. Epub 2005 Jul 7.
• [54] Peroxisome proliferator-activated receptor-gamma ligands suppress fibronectin gene expression in human lung carcinoma cells: involvement of both CRE and Sp1. Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L419-28. doi: 10.1152/ajplung.00002.2005. Epub 2005 May 20.
• [55] Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat. 2008 Mar;108(1):23-33. doi: 10.1007/s10549-007-9575-y. Epub 2007 Apr 24.
• [56] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [57] Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology. 2007 Feb;148(2):903-11. doi: 10.1210/en.2006-1121. Epub 2006 Nov 22.
• [58] Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1577-81. doi: 10.1161/01.atv.19.6.1577.
• [59] Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care. 2006 May;29(5):1071-6. doi: 10.2337/diacare.2951071.
• [60] PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009 Jul;297(1):E174-83. doi: 10.1152/ajpendo.90632.2008. Epub 2009 May 5.
• [61] VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8(1):16092. doi: 10.1038/s41598-018-34259-0.
• [62] Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol. 2006 Aug 28;72(5):530-40. doi: 10.1016/j.bcp.2006.05.009. Epub 2006 Jun 27.
• [63] Methamphetamine exposure upregulates the amyloid precursor protein and hyperphosphorylated tau expression: The roles of insulin signaling in SH-SY5Y cell line. J Toxicol Sci. 2019;44(7):493-503. doi: 10.2131/jts.44.493.
• [64] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [65] Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp Cell Res. 2011 Jun 10;317(10):1397-410. doi: 10.1016/j.yexcr.2011.02.014. Epub 2011 Mar 3.
• [66] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [67] Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol. 2009 Jul;76(1):183-91. doi: 10.1124/mol.109.056028. Epub 2009 Apr 15.
• [68] Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. Eur J Clin Invest. 2003 Jul;33(7):574-81. doi: 10.1046/j.1365-2362.2003.01178.x.
• [69] Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem. 2001 Aug 17;276(33):31059-66. doi: 10.1074/jbc.M104141200. Epub 2001 Jun 7.
• [70] Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett. 2009 Mar 18;275(2):247-55. doi: 10.1016/j.canlet.2008.10.023. Epub 2008 Dec 3.
• [71] Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. Toxicol Sci. 2005 Feb;83(2):293-302. doi: 10.1093/toxsci/kfi022. Epub 2004 Nov 3.
• [72] Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):523-30. doi: 10.1111/j.1742-7843.2010.00539.x. Epub 2010 Feb 22.
• [73] Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension. 2008 Feb;51(2):259-66. doi: 10.1161/HYPERTENSIONAHA.107.099028. Epub 2007 Dec 24.
• [74] Impact of rosiglitazone on the expression of beta3-AR in the stable cell lines expressed beta3-AR gene. Clin Chem Lab Med. 2007;45(11):1511-6. doi: 10.1515/CCLM.2007.315.
• [75] Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR- and subsequent expression of HGF in colons. Toxicol Appl Pharmacol. 2018 Mar 15;343:1-15. doi: 10.1016/j.taap.2018.02.001. Epub 2018 Feb 3.
• [76] Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
• [77] Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia. 2005 Jun;48(6):1173-9. doi: 10.1007/s00125-005-1741-3. Epub 2005 Apr 30.
• [78] Rosiglitazone protects neuroblastoma cells against advanced glycation end products-induced injury. Acta Pharmacol Sin. 2011 Aug;32(8):991-8. doi: 10.1038/aps.2011.81. Epub 2011 Jul 18.
• [79] Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J Pharmacol Exp Ther. 2004 Nov;311(2):467-75. doi: 10.1124/jpet.104.068254. Epub 2004 Jul 23.
• [80] Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis. 2008 Jul;199(1):55-64. doi: 10.1016/j.atherosclerosis.2007.10.038. Epub 2008 Feb 21.
• [81] Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer. 2010 Feb 18;17(1):169-77. doi: 10.1677/ERC-09-0170. Print 2010 Mar.
• [82] Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells. Biochem Biophys Res Commun. 2008 Feb 1;366(1):149-55. doi: 10.1016/j.bbrc.2007.11.095. Epub 2007 Nov 29.
• [83] Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem Pharmacol. 2004 Jul 1;68(1):155-63. doi: 10.1016/j.bcp.2004.03.009.
• [84] Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. Am J Pathol. 2007 Feb;170(2):722-32. doi: 10.2353/ajpath.2007.060651.
• [85] Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol. 2006 Apr 28;71(9):1308-23. doi: 10.1016/j.bcp.2006.01.011. Epub 2006 Feb 23.
• [86] Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells. Cytokine. 2007 Sep;39(3):184-91. doi: 10.1016/j.cyto.2007.07.191. Epub 2007 Sep 5.
• [87] Rosiglitazone, an Agonist of PPARgamma, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2. PPAR Res. 2007;2007:29632. doi: 10.1155/2007/29632.
• [88] Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin B receptor. Hypertension. 2010 Jul;56(1):129-35. doi: 10.1161/HYPERTENSIONAHA.110.150375. Epub 2010 Jun 1.
• [89] Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals. Mol Cancer Ther. 2009 Jan;8(1):110-8. doi: 10.1158/1535-7163.MCT-08-0719.
• [90] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [91] Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells. J Biol Chem. 2006 May 12;281(19):13503-13512. doi: 10.1074/jbc.M510357200. Epub 2006 Mar 9.
• [92] Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer. 2006 May 15;118(10):2390-8. doi: 10.1002/ijc.21799.
• [93] 9-cis-Retinoic acid (9cRA), a retinoid X receptor (RXR) ligand, exerts immunosuppressive effects on dendritic cells by RXR-dependent activation: inhibition of peroxisome proliferator-activated receptor gamma blocks some of the 9cRA activities, and precludes them to mature phenotype development. J Immunol. 2007 May 15;178(10):6130-9. doi: 10.4049/jimmunol.178.10.6130.
• [94] [Effects of rosiglitazone on the Hep-2 cell proliferation, cell cycle and COX-2 expression]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Apr;24(7):315-7.
• [95] Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes. Biochimie. 2003 Dec;85(12):1257-64. doi: 10.1016/j.biochi.2003.10.016.
• [96] Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis. Mol Hum Reprod. 2013 May;19(5):313-26. doi: 10.1093/molehr/gat002. Epub 2013 Jan 11.
• [97] 2,2',4,4'-Tetrabromodiphenyl Ether (PBDE 47) Selectively Stimulates Proatherogenic PPAR Signatures in Human THP-1 Macrophages to Contribute to Foam Cell Formation. Chem Res Toxicol. 2022 Jun 20;35(6):1023-1035. doi: 10.1021/acs.chemrestox.2c00043. Epub 2022 May 16.
• [98] Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol. 2010 Feb;44(2):135-42. doi: 10.1677/JME-09-0090. Epub 2009 Oct 22.
• [99] Effects of Perinatal Exposure to Dibutyltin Chloride on Fat and Glucose Metabolism in Mice, and Molecular Mechanisms, in Vitro. Environ Health Perspect. 2018 May 21;126(5):057006. doi: 10.1289/EHP3030. eCollection 2018 May.
• [100] Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice. Toxicol Appl Pharmacol. 2015 May 15;285(1):61-70. doi: 10.1016/j.taap.2015.03.011. Epub 2015 Mar 18.
• [101] The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005 Jan;48(1):83-95. doi: 10.1007/s00125-004-1619-9. Epub 2004 Dec 24.
• [102] Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007 Jun;28(6):879-87. doi: 10.1111/j.1745-7254.2007.00571.x.
• [103] PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Biochem Biophys Res Commun. 2003 Apr 11;303(3):782-7. doi: 10.1016/s0006-291x(03)00418-2.
• [104] Tributyltin and triphenyltin induce 11-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor . Toxicol Lett. 2020 Apr 1;322:39-49. doi: 10.1016/j.toxlet.2020.01.001. Epub 2020 Jan 9.
• [105] Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism. Environ Health Perspect. 2012 Jul;120(7):984-9. doi: 10.1289/ehp.1205063. Epub 2012 May 25.
• [106] Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res. 2004 Nov;45(11):2015-24. doi: 10.1194/jlr.M400049-JLR200. Epub 2004 Aug 16.
• [107] Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond). 2007 Aug;31(8):1302-10. doi: 10.1038/sj.ijo.0803567. Epub 2007 Feb 20.
• [108] PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther. 2006 Aug;5(8):1008-14. doi: 10.4161/cbt.5.8.2887. Epub 2006 Aug 7.
• [109] Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun. 2002 Jan 11;290(1):131-9. doi: 10.1006/bbrc.2001.6141.
• [110] The effect of rosiglitazone on LRP1 expression and amyloid uptake in human brain microvascular endothelial cells: a possible role of a low-dose thiazolidinedione for dementia treatment. Int J Neuropsychopharmacol. 2012 Feb;15(1):135-42. doi: 10.1017/S1461145711001611. Epub 2011 Nov 1.
• [111] Involvement of peroxisome proliferator-activated receptor gamma (PPAR) and autophagic pathways in the mechanism of action of the tris(2,3-dibromopropyl) isocyanurate (TDBP-TAZTO or TBC) flame retardant in the lung adenocarcinoma (A549) cells in vitro. J Appl Toxicol. 2023 Sep;43(9):1358-1367. doi: 10.1002/jat.4470. Epub 2023 Mar 31.
• [112] Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007 Oct;30(9):RC26-30. doi: 10.1007/BF03350807.
• [113] Selective Tissue Distribution Mediates Tissue-Dependent PPAR Activation and Insulin Sensitization by INT131, a Selective PPAR Modulator. Front Pharmacol. 2017 May 30;8:317. doi: 10.3389/fphar.2017.00317. eCollection 2017.
• [114] Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004 Aug;53(8):2169-76. doi: 10.2337/diabetes.53.8.2169.
• [115] Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue. Diabetes. 2006 Mar;55(3):640-50. doi: 10.2337/diabetes.55.03.06.db05-1015.
• [116] Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Diabetologia. 2006 Jun;49(6):1303-10. doi: 10.1007/s00125-006-0228-1. Epub 2006 Apr 12.
• [117] Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance. Patholog Res Int. 2011 Apr 12;2011:736425. doi: 10.4061/2011/736425.
• [118] Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia. 2005 Aug;48(8):1585-9. doi: 10.1007/s00125-005-1835-y. Epub 2005 Jul 1.
• [119] Bisphenol A and its derivatives decrease expression of chemerin, which reverses its stimulatory action in ovarian cancer cells. Toxicol Lett. 2018 Jul;291:61-69. doi: 10.1016/j.toxlet.2018.04.004. Epub 2018 Apr 10.
• [120] PPAR- activation attenuates deltamethrin-induced apoptosis by regulating cytosolic PINK1 and inhibiting mitochondrial dysfunction. Toxicol Lett. 2016 Oct 17;260:8-17. doi: 10.1016/j.toxlet.2016.08.016. Epub 2016 Aug 21.
• [121] Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncol Rep. 2008 Nov;20(5):1093-7.
• [122] Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull. 2011;34(7):1120-1. doi: 10.1248/bpb.34.1120.
• [123] Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. J Clin Endocrinol Metab. 2005 Dec;90(12):6678-86. doi: 10.1210/jc.2005-0079. Epub 2005 Oct 4.
• [124] Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos. 2011 Apr;39(4):711-6. doi: 10.1124/dmd.110.035899. Epub 2011 Jan 18.
• [125] Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care. 2010 Oct;33(10):2250-3. doi: 10.2337/dc10-0452. Epub 2010 Jul 13.
• [126] LPIN1 genetic variation is associated with rosiglitazone response in type 2 diabetic patients. Mol Genet Metab. 2008 Sep-Oct;95(1-2):96-100. doi: 10.1016/j.ymgme.2008.06.011. Epub 2008 Aug 9.